Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States

The head-to-head AIDS Clinical Trial Group (ACTG) 5257 clinical trial found raltegravir (RAL) to be superior to atazanavir + ritonavir (ATV/r) and darunavir + ritonavir (DRV/r), when used in combination with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) by treatment-naive adults with HIV-1 i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Brogan, Anita J., Davis, Ashley E., Goodwin, Bridgett
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6117059/
https://ncbi.nlm.nih.gov/pubmed/30161205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0203293
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares